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This paper presents a protocol for routine assays
of human blood cholinesterase activities which
separates erythrocytes from plasma by
centrifugation and measures acetylcholinesterase
activity in unwashed erythrocytes and butyrylcho-
linesterase activity in the plasma. The
recommended substrate for both enzymes is 1.0 mM
acetylthiocholine. The protocol is compared with
other two recommended protocols for the activity
measurements of the two enzymes using the
Ellman method. The paper discusses the
advantages and disadvantages of each and
concludes with a proposal for an international
agreement between laboratories for the evaluation
of a standardized protocol.
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Absorption of organophosphorus compounds or carbamates is commonly assessed
by measuring the decrease in acetylcholinesterase (AChE; EC 3.1.1.7) or butyrylcho-
linesterase (BChE; EC 3.1.1.8) activities in human blood. The primary toxic effect of
organophosphates and carbamates is inhibition of AChE. However, many compounds
better inhibit BChE than AChE , in which case BChE is a better indicator of absorp-
tion. As there is no general rule to predict which enzyme will be more inhibited by a
given compound, one should measure the activity of both cholinesterases in human
blood in order to detect the absorption of inhibitors more reliably.
Erythrocyte AChE activities are usually measured in whole blood, and the most
commonly used substrate is acetylthiocholine (ATCh). As whole blood also contains
BChE, the rate of substrate hydrolysis in whole blood depends on the activity of both
enzymes. The procedure for determination of BChE activity in human plasma or
serum is well established, while this is not the case with the erythrocyte AChE.
In this paper we propose a procedure based upon separation of plasma from
erythrocytes, followed by separate measurements of BChE in plasma and AChE in
unwashed erythrocytes. The procedure has been prepared for presentation at the
Third Chemical and Biological Medical Treatment Symposium (1, 2).
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EXPERIMENTAL PROCEDURE AND CONDITIONS
The activities of AChE and BChE were measured by the spectrophotometric method
of Ellman and co-workers (3).
Venous blood was collected into dried heparinised tubes. After blood centrifuga-
tion, plasma was separated from the erythrocytes. In that step it was essential to
withdraw all plasma without withdrawing any erythrocytes. The erythrocytes were then
suspended in deionised water in a volume corresponding to the initial volume of the
whole blood, diluted 60-fold with a buffer (0.1 M phosphate buffer, pH=7.4), and
then frozen for haemolysis. After thawing, the suspension was further diluted with the
buffer (9-fold) and the thiol reagent 5,5'-dithio-bis(2-nitro benzoic acid) (DTNB) was
added. The final DTNB concentration during the enzyme assay was 0.33 mM. Ten
minutes after the addition of DTNB, the substrate ATCh was added (the final ATCh
concentration during the enzyme assay was 1.0 mM) to the suspension and the
increase in absorbance was read at 412 nm against a blank containing haemolysed
erythrocytes suspended in buffer. The BChE activity in plasma was also measured
with 1.0 mM ATCh using the same buffer and DTNB concentration. The final assay
volume for both enzymes was 3.0 ml. Stock solutions of ATCh (100 mM) were pre-
pared in deionised water whereas further dilutions were made in the buffer. Stock
solutions of DTNB (10 mM) were prepared in the buffer. During the enzyme assay,
the final dilution of erythrocytes was 600-fold and that of plasma 150-fold. The en-
zyme activities were measured at 25 oC or 37 oC.
The concentration of haemoglobin in the erythrocyte suspension was determined
spectrophotometrically with a modified Zijlstra reagent containing potassium ferricya-
nide, potassium cyanide, sodium bicarbonate, and Triton X-100 (4). The final reac-
tion volume was 1.5 ml and the final erythrocyte dilution was 120-fold. The absor-
bance was read at 546 nm against buffer at room temperature.
The activities of AChE were expressed as micromoles of hydrolysed ATCh per
minute and per milliliter of whole blood, or per milligram haemoglobin or per micro-
mole iron. The activities of BChE were expressed as micromoles of hydrolysed ATCh
per minute and per milliliter of plasma. The molar coefficient of absorbance used in this
study for the thiolate anion of the 5-thio-2-nitro benzoic acid was 13600 M-1 cm-1 (3)
and for haemoglobin 10800 M-1 cm-1 (4 ).
RESULTS AND DISCUSSION
Evaluation of the suggested protocol
The described experimental conditions concerning the choice of the buffer and sub-
strate were evaluated in an earlier study concerning routine measurements of cho-
linesterase activities in the human whole blood and plasma (5). The phosphate buffer
was chosen because the effect of temperature on the pH of that buffer is small and
the buffer can therefore be prepared at the room temperature and used at a temper-
ature ranging from 10 oC to 40 oC. ATCh is a suitable substrate for both AChE and
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BChE. For routine purposes it is convenient to use the same substrate concentration
(1.0 mM) for both enzymes. At 1.0 mM of ATCh, AChE has its optimal activity and
BChE about half of its maximum activity. The rate of spontaneous hydrolysis of 1.0 mM
ATCh at pH=7.4 is slow and corrections for the non-enzymic substrate hydrolysis are
required only at 37 oC.
The optical density of the haemolysed unwashed erythrocytes measured at 412 nm
is not stable. The absorbance measured against buffer decreases about 0.006 absor-
bance units over 10 min at 25 oC or 37 oC (mean value of 12 measurements on
erythrocyte samples from 7 individuals). That decrease is very small and need not be
taken into account, particularly if the activities are measured against suspended haemolysed
unwashed erythrocytes as a blank.
DTNB reacts not only with thiocholine, but also with thiol groups in the haemolysed
erythrocytes. Under the above experimental conditions, the reaction between DTNB
and thiol groups in the haemolysed erythrocytes is completed within 10 min, and this
is why it is suggested to add the substrate 10 min after adding DTNB. The reaction
between DTNB and thiol groups in the erythrocytes reduces the DTNB concentration
by only about 0.5% (mean value of 20 measurements on erythrocyte samples from
10 individuals).
The suggested procedure is well reproducible. The within-run and between-run
imprecision for the activity measurements of AChE in unwashed haemolysed erythro-
cytes was 2% each, and for the haemoglobin determination 1% each. The corre-
sponding imprecisions for plasma BChE activity measurements were 1–3 and 6–7%
(6 and this paper).
Comparison with protocols suggested by other authors
Several procedures have been suggested so far to measure the erythrocyte AChE in
the whole blood. Worek and co-workers (4) suggest that the AChE activity be mea-
sured in the presence of 20 µM ethopropazine in order to inhibit plasma BChE in the
whole blood. Wicki (7) and Portmann (8, 9) suggest that both AChE and BChE be
measured in the whole blood by successive addition of ATCh and butyrylthiocholine
(BTCh). Reiner and co-workers (5, 10) assessed the erythrocyte AChE activity by
measuring the rate of hydrolysis of 1.0 mM ATCh in the whole blood, as under these
conditions the rate of hydrolysis primarily depends on the erythrocyte AChE. Finally,
one can separate erythrocytes from plasma by centrifugation, wash the erythrocytes
with saline or buffer, and measure AChE activities in washed erythrocytes as described
by Ellman and co-workers (3). Our procedure outlined in this paper also separates
erythrocytes from plasma, but AChE is measured in unwashed erythrocytes.
The following is an assessment of advantages and disadvantages of each of the
above protocols.
Unwashed erythrocytes might contain some residual plasma. In order to test
whether BChE in the residual plasma affects the AChE activity in unwashed erythro-
cytes, we applied ethopropazine as a potent BChE inhibitor. Ethopropazine (20 µM)
inhibited the hydrolysis of 1.0 or 0.5 mM ATCh by 8.8% in unwashed erythrocytes and
by 8.5% in washed erythrocytes (mean values of 16 measurements on samples from
6 individuals). The difference between inhibition of washed and unwashed erythro-
cytes is very small and indicates that BChE in the residual plasma did not show up
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in the assay, because otherwise the inhibition in unwashed erythrocytes would be
higher than in washed erythrocytes. We therefore think that it is not necessary to
wash erythrocytes before the AChE assay, particularly because washing might cause
haemolysis. The above result further indicates that the 8–9% inhibition measured in
erythrocytes must be attributed to the inhibition of AChE, which is in agreement with
the 5% inhibition of AChE reported by Worek and co-workers (4).
We further tested the proposed protocol by measuring the cholinesterase activity of
the whole blood with 1.0 mM ATCh without separating the erythrocytes from plasma.
Knowing the haematocrit, the cholinesterase activity of the whole blood sample was
calculated as the sum of separate measurements of AChE in unwashed erythrocytes and
BChE in plasma. The mean values of the measured and calculated activities in samples
from 15 individuals were in very good agreement: 7.16 and 6.97 µmol min-1 ml-1, respec-
tively.
We think that our protocol is suitable for routine assays, particularly because we
suggest to measure both enzymes with the same substrate (ATCh) and with the same
substrate concentration (1.0 mM). The protocol, however, requires centrifugation of
whole blood and careful separation of plasma from erythrocytes. This is a disadvan-
tage for the separation of stored blood samples which are usually haemolysed.
Worek and co-workers (4) suggest an AChE assay in whole blood with ATCh as
substrate, but in the presence of ethopropazine (20 µM) in order to inhibit BChE.
When ethopropazine is applied as a selective inhibitor of plasma BChE one should
bear in mind that the usual BChE phenotype is 98% inhibited with 20 µM ethopro-
pazine, while the atypical BChE phenotype is inhibited only 74%, and the heterozygots
of the atypical variant between 94 and 85% (11). The occurrence of BChE pheno-
types other than the usual is rare in Caucasian populations and the activities of BChE
phenotypes other than UU are much smaller than the UU activities (12–14). The
errors in estimated AChE activities due to the presence of BChE phenotypes other
than UU will therefore be small and will rarely occur. Worek and co-workers (4)
further suggest that plasma BChE is measured with BTCh as a substrate. Conse-
quently, determination of AChE and BChE suggested by Worek and co-workers (4)
requires two different substrates, one selective inhibitor, and centrifugation of the
whole blood to obtain the plasma.
In the procedure of Wicki (7) and Portmann (8, 9) AChE and BChE are both
measured in the whole blood. The activity of both enzymes is first measured with ATCh
(1.0 mM) after which BTCh (5.0 mM) is added to the same cuvette and the activity
measurement continued. The calculation of AChE and BChE activities is based on the
assumption that BTCh is hydrolysed only by BChE and that the addition of BTCh stops
the hydrolysis of ATCh. The advantage of this protocol is that it does not require blood
centrifugation. One should, however, bear in mind that BTCh is not fully specific for
BChE, but is also hydrolysed by AChE, although at a considerably slower rate. We
obtained the following mean activities of washed erythrocytes in samples from 5 indi-
viduals: 4.35 µmol min-1 ml-1 measured with 1.0 mM ATCh and 0.31 µmol min-1 ml-1
measured with 5.0 mM BTCh.
The AChE activities can be expressed either per volume of whole blood, per hae-
moglobin content, or per iron content. We measured the AChE activities with 1.0 mM
ATCh in unwashed erythrocytes obtained from 15 individuals. The mean activities (±SD)
were 5.44±0.68 mmol min-1 ml-1BLOOD and 0.661±0.080 µmol min-1 µmol -1IRON.
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This means that the relative standard deviations of the mean were 12–13% irrespective
of how the activities were expressed. However, the mean haemoglobin (iron) con-
centrations in these 15 samples were 8.82 µmolIRON ml-1 in the whole blood and
8.28 µmolIRON ml-1 in unwashed erythrocytes. The difference is small, but it might
point to a slight loss of haemoglobin due to withdrawal of plasma following cen-
trifugation of blood.
CONCLUSION
A standardised protocol for measuring AChE and BChE activities in human blood is
needed. That protocol should be simple in technical terms and should give reliable
and well reproducible results. Each of the above described protocols has its own
advantages and disadvantages. The protocol of choice should be based on an inter-
national agreement between laboratories following an interlaboratory quality control
study on samples over a wide range of AChE and BChE activities in the whole blood.
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Sa‘etak
USPOREDBA PROTOKOLA ZA MJERENJE AKTIVNOSTI
KOLINESTERAZA U LJUDSKOJ KRVI ELLMANOVOM METODOM
Mjerenjem aktivnosti acetilkolinesteraze i butirilkolinesteraze u krvi mo‘e se u osoba izlo‘enih organofosfornim
spojevima i karbamatima odrediti apsorpcija tih spojeva. Za mjerenje aktivnosti butirilkolinesteraze u ljudskoj
plazmi postoji standardizirani protokol usvojen u velikom broju klini~kih i toksikolo{kih laboratorija, dok za mjerenje
aktivnosti eritrocitne acetilkolinesteraze ima nekoliko predlo‘enih protokola, ali ni jedan jo{ nije op}e priva}en.
Zajedni~ki princip svih predlo‘enih protokola je spektrofotometrijska Ellmanova metoda, koja za mjerenje aktivosti
kolinesteraza rabi tiokolinske supstrate. Autori ovoga rada predla‘u jednostavni protokol u kojem se zasebno mjere
aktivnosti u plazmi i u eritrocitima, koji nisu prani, a koji se odvoje centrifugiranjem. Aktivnost u eritrocitima mjeri
se nakon hemolize eritrocita smrzavanjem. MjerI se samo s 1,0 mM acetiltiokolinom. Drugi autori mjere aktivnost u
punoj krvi koriste}i se dvama supstratima (acetiltiokolinom i butiriltiokolinom), koji se u hemoliziranu krv dodaju
sukcesivno i nakon svakog dodavanja supstrata mjeri se aktivnost. Neki autori predla‘u uporabu etopropazina,
specifi~nog inhibitora butirilkolinesteraze, pa se mjerenje vr{i u prisutnosti i odsutnosti toga inhibitora. U ovome su
radu opisane prednosti i nedostaci pojedinog protokola te izvori mogu}ih pogre{aka u predlo‘enim postupcima. Za
usvajanje standardiziranog protokola za mjerenje aktivnosti eritrocitne kolinesteraze potreban je dogovor autora
predlo‘enih protokola nakon ~ega bi trebala uslijediti me|ulaboratorijska provjera toga protokola.
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acetilkolinesteraza, butirilkolinesteraza, ljudska plazma, ljudski eritrociti, preciznost mjerenja, etopropazin
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